Screener
ANI Pharmaceuticals ANIP Other income, net (Note 6)
Other income, net (Note 6) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other (expense) income, net | ||||
| Unrealized gain (loss) on investment in equity securities | 741 | 332 | 6,494 | (589) |
| Interest expense, net | (3,636) | (5,438) | (7,405) | (10,922) |
| Other (expense) income, net | (468) | 1,739 | (1,119) | 1,937 |
| Income Before Income Tax Expense | 37,097 | 10,525 | 77,318 | 30,512 |
| Income tax expense | 12,386 | 1,976 | 23,115 | 6,282 |
| Net Income | $24,711 | $8,549 | $54,203 | $24,230 |
| Dividends on Series A Convertible Preferred Stock | — | (407) | — | (813) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's other income, net (note 6)?
- ANI Pharmaceuticals (ANIP) reported other income, net (note 6) of -$468K in Q2 2026.
- How has ANI Pharmaceuticals's other income, net (note 6) changed year-over-year?
- ANI Pharmaceuticals's other income, net (note 6) decreased by 126.9% year-over-year, from $1.74M to -$468K.
- What is the long-term trend for ANI Pharmaceuticals's other income, net (note 6)?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's other income, net (note 6) has grown at a -18.3% compound annual growth rate (CAGR), from -$4.34M to $1.93M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about ANI Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude